Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: A pathologic analysis  by Denton, Mark D. et al.
Kidney International, Vol. 61 (2002), pp. 2201–2209
Prevalence of renal cell carcinoma in patients with ESRD
pre-transplantation: A pathologic analysis
MARK D. DENTON, COLM C. MAGEE, CYRIL OVUWORIE, SHAMILA MAUIYYEDI,
MANUEL PASCUAL, ROBERT B. COLVIN, A. BENEDICT COSIMI, and NINA TOLKOFF-RUBIN
Renal Division, Department of Medicine, Brigham and Women’s Hospital, Department of Nephrology, Department of
Pathology and Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Prevalence of renal cell carcinoma in patients with ESRD pre- croscopic cysts can be identified in the kidney biopsies
transplantation: A pathologic analysis. of some patients with chronic renal impairment [3], cysts
Background. Acquired renal cystic disease (ARCD), renal are not usually detected radiologically until the develop-adenoma (AD), and renal cell carcinoma (RCC) are more com-
ment of ESRD. ARCD increases in prevalence and se-mon in patients with end-stage renal disease (ESRD). How-
verity with increasing years on dialysis: 20% of patientsever, the prevalence of these conditions in patients undergoing
transplantation, and the clinical characteristics associated with dialyzed for 1 to 3 years have ARCD, compared with
their occurrence are unclear. greater than 90% of patients dialyzed for 5 to 10 years
Methods. At our institution, the majority of patients undergo
[2]. The prevalence of renal cell carcinoma (RCC) alsoan ipsilateral native nephrectomy at the time of transplantation,
is increased in patients with ESRD on dialysis [4] andproviding a unique opportunity to study the prevalence and
pathology of ARCD, AD and RCC in ESRD. We retrospec- in patients after renal transplantation [5]. By ultrasound,
tively reviewed all consecutive nephrectomy pathology reports RCC was identified in the native kidneys of 3.8% and
over a six year period. Demographic and clinical characteristics 3.9% of ESRD patients pre- and post-transplantation,associated with these lesions were identified.
respectively [4, 5], which represents a 100-fold increaseResults. Two hundred and sixty nephrectomy reports were
in prevalence compared to the general population.reviewed: ARCD, AD, RCC and oncocytoma were found in
33%, 14%, 4.2% and 0.6% of cases, respectively. On multivari- Most studies examining the prevalence of ARCD and
able analysis, ARCD was positively associated with male sex RCC in the ESRD population are based on radiological
and longer dialysis duration and negatively associated with
detection. However, radiological techniques may under-peritoneal dialysis. Similarly, AD was positively associated with
estimate the true prevalence of ARCD and RCC due tomale sex, longer dialysis duration and greater age. There was
a trend for RCC cases to share similar associations although limitations in resolution. At our institution, ureteropye-
the small total number of cases precluded findings of statistical lostomy, using the recipient ureter, is the preferred method
significance. of urinary tract reconstruction for renal allograft recipi-Conclusion. By pathologic analysis, renal tumors are more
ents who are free of vesicoureteric reflux or other ure-common in the pre-transplant ESRD population than previ-
teral abnormalities [6]. Thus, ipsilateral native nephrec-ously reported (using radiologic methods). Our study also iden-
tifies risk factors for their occurrence. This may prove useful tomy is performed on the majority of patients undergoing
in designing screening studies for renal tumors in this patient renal transplantation. All nephrectomy specimens are ex-
population.
amined macroscopically, microscopically and by immuno-
fluorescence. Using this unique database, we performed
a retrospective analysis to determine the prevalence ofAcquired renal cystic disease (ARCD) is character-
ARCD, AD and RCC in ESRD patients undergoing renalized by the development of multiple cysts in the kidneys
transplantation. This study identifies clinical risk factorsof patients with end-stage renal disease (ESRD), in the
associated with RCC that may provide a framework forabsence of congenital cystic disease [1, 2]. Although mi-
selective screening of the pre-transplant population.
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Table 1. Demographic and clinical characteristics of the 260 patientsureteroneocystostomies. The principle reason for not
who underwent nephrectomy
performing nephrectomy and ureteropyelostomy was a
Characteristic N (%)history of vesicoureteric reflux. The medical records of
Sexall patients who had had a nephrectomy were examined
Male 161 (61.9)and the following clinical information was systematically
Race
extracted: age, sex, primary renal disease, dialysis mod- White 207 (79.6)
Black 27 (10.4)ality, and duration. Data on smoking history were not
Hispanic 15 (5.7)uniformly available. Diagnosis of primary renal disease
Asian 12 (4.6)
was based on clinical history, histologic examination of Dialysis
Total 209 (80.3)prior biopsy samples or the nephrectomy specimen.
HD 162 (62.3)At the time of nephrectomy, specimens were thinly
PD 47 (18.1)
sliced at 0.5 cm intervals and examined macroscopically Primary disease
GN 95 (36.5)for cysts and tumors. Routinely, 3 to 5 random sections
DM 54 (20.7)were examined by hematoxylin and eosin (H&E) and
PKD 33 (12.7)
periodic acid-Schiff (PAS) staining for original disease HTN 18 (6.9)
CP/reflux 14 (5.4)as well as for the presence of acquired renal cystic disease
Dysplasia 8 (3.1)and neoplasia, including benign tumors (adenoma, onco-
Others 38 (14.6)
cytoma) and renal cell carcinoma. In addition, sections Mean or median
Age years 42.7 (mean)12.7 (SD)from gross lesions were examined. Pathologic criteria for
Dialysis duration years 1.0 (median); 0–16 (range)the presence of ARCD included scattered macroscopic
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; GN, glomerulo-cystic structures occupying more than 25% of the renal
nephritis; DM, diabetes mellitus; PKD, polycystic kidney disease; HTN, hyper-
parenchyma or3 cysts per kidney [7]. The renal tumors tension; CP, chronic pyelonephritis.
were characterized by histologic type, as classified by the
Heidelberg classification [8]. The criteria of Grignon and
Eble were used for papillary lesions, that is, tumors with
not significant by univariable analysis), as the purpose ofa diameter less than 0.5 cm were considered adenomas
the study was to identify all possible clinical or statisti-[9]. All clear cell tumors were considered malignant ac-
cally significant predictors. Where more than two cate-cording to the view of these authors. The renal cell carci-
gorical variables existed, dummy coding was performed.nomas were graded according to a four-tier system based
Variables that became non-significant in the multivari-on nuclear size, shape and content as proposed by Fuhr-
able models were tested for colinearity and confounding.man et al [10]. Staging was performed using the TNM sys-
Results are presented as odds ratios with 95% confi-tem [11]. All cases of RCC were subsequently confirmed
dence intervals and with P values. A P value 0.05 wasat the time of analysis by two authors (SM and RC).
considered statistically significant. SAS (Cary, NC, USA)The prevalence of ARCD, AD and RCC were deter-
was used for statistical analysis.mined and correlated with clinical variables by retrospec-
tive analysis of the database. Follow-up abdominal im-
aging after transplantation in cases with RCC also was RESULTS
done.
Population characteristics
Statistical analysis The demographic and clinical characteristics of the 260
patients who underwent native nephrectomy at trans-Descriptive and univariable analysis. Categorical pre-
plantation are listed in Table 1. Over 60% were male;dictors were first tabulated to determine whether ade-
the majority were white and almost 2/3 were on dialysisquate numbers (for meaningful statistical analyses) ex-
prior to transplantation. Further analysis compared whitesisted per category and thus whether to group or leave
to non-whites. Interestingly, the most commonly identi-unchanged. Grouping was then only performed if clini-
fied cause of primary renal disease was glomerular incally relevant. In each analysis, the outcome was a binary
origin and included IgA nephropathy, membranoproli-variable: ARCD/no ARCD and AD/no AD. Categorical
ferative glomerulonephritis, membranous glomerulone-predictors were individually compared to the outcomes
phritis, focal segmental glomerulosclerosis and crescenticby Fisher’s exact test; continuous variables were com-
glomerulonephritis.pared using the Wilcoxon rank sum test.
Multivariable analysis. Logistic regression was then used
Acquired renal cystic diseasefor determination of predictors significantly associated
Of all nephrectomy specimens with ESRD, 33% (85/with each of the three different outcomes (presence of
260) had ARCD (Fig. 1B) characterized by the presenceARCD, presence of AD, presence of RCC). All predictors
were carried forward to the regression model (even if of variable sized cysts scattered in the renal parenchyma
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lined by flat or cuboidal epithelium that focally showed cytoma. The clinical and pathological features of the 11
reactive nuclear changes and micropapillary projections. cases of RCC are outlined in Table 6. RCC was detected
The cysts were scattered singly or sometimes in small in 4.2% (11/260) of the nephrectomy specimens. Of these,
clusters. 55% (6/11) had conventional, clear cell, renal carcinoma
The demographic and clinical characteristics of pa- (Fig. 1E), with cystic change in three cases. Four of the
tients grouped according to the presence or absence of remaining cases and one case that also had coexisting
ARCD are listed in Tables 2 and 3. On univariable analy- clear cell carcinoma, were papillary renal carcinomas
sis (Table 2), patients with ARCD were older, more (45%; Fig. 1F); three basophilic type (type 1) and two
likely to be male, to have undergone hemodialysis and eosinophilic type (type 2). The remaining case was a
to have a primary renal diagnosis of glomerulonephri- chromophobe renal carcinoma (9%) with positive stain-
tis compared to patients without ARCD. No difference ing for colloidal iron (Fig. 1 G, H). All the renal cell
in race was noted between the groups. The mean dura- carcinomas in our series were T1N0M0 lesions (stage I),
tion of dialysis was significantly longer in patients with limited to the kidney.
ARCD. No difference between the two groups was seen In the 11 cases of RCC, 91% (10/11) had underlying
with regard to “exposure” to peritoneal dialysis. The ad- ARCD and 73% (8/11) had coexisting papillary AD.
justed (multivariable) analysis (Table 3) showed that Indeed, RCC was highly associated with both ARCD
only male sex and dialysis duration were significantly (OR 6.0, 1.5 to 23.1; P 0.007) and AD (OR 38.6, 7.9 to
associated with the presence of ARCD. Interestingly, 188.3; P  0.001). In 36% (4/11) of cases, subsequent
peritoneal dialysis was inversely associated with ARCD radiological investigation revealed the presence of a tu-
on the adjusted analysis; the lack of significance in univa- mor (confirmed in all cases by subsequent histology) in
riable analysis mainly reflected negative confounding by the contralateral kidney. The majority of bilateral tumors
dialysis duration. exhibited papillary morphology. The clinical characteris-
tics of patients grouped according to the presence or ab-Renal adenomas
sence of RCC are listed in Table 7 (univariable analysis)
Renal adenomas were identified in 14% (35/260) of and Table 8 (multivariable analysis). On multivariable
the end-stage kidneys. AD were typically 0.2 to 0.4 cm analysis only age reached significance; there was only a
in diameter in our series and showed either a papillary, trend towards significance with male sex and dialysis
tubular, or tubulopapillary pattern, without clear cell
duration probably because group numbers were small.change or nuclear abnormalities, consistent with papil-
Patients were followed for a mean of 31.3 22.5 monthslary renal adenomas (Fig. 1C).
after transplantation. During this period, two more casesThe demographic and clinical characteristics of pa-
of RCC were diagnosed in the contralateral native kid-tients grouped according to the presence or absence of
ney, found incidentally on radiological examination. Nei-AD are listed in Table 4 (univariable analysis) and Ta-
ther patient had previously been diagnosed with RCC.ble 5 (multivariable analysis). On univariable analysis,
No cases of metastatic renal cell carcinoma occurred.patients with AD shared similar characteristics to those
with ARCD including greater age, a higher likelihood
of male sex, and longer dialysis duration. Interestingly, DISCUSSION
the presence of AD was again correlated with the pri-
Dunhill, Millard and Oliver first described the associa-
mary renal disease. Patients with AD were significantly
tion of ARCD and RCC with hemodialysis [12]. In hismore likely to have a glomerulonephritis as the primary
autopsy study of 40 patients, 46% had ARCD and 15%renal disease. In contrast, diabetes inversely correlated
had a renal tumor. Miller et al subsequently reported awith the presence of AD. Indeed, diabetes was the under-
larger autopsy series of 155 hemodialysis patients inlying cause of ESRD in only one patient (2.9%) with an
which ARCD was noted in 58%, renal adenoma in 16%,AD in contrast to a prevalence of 23.6% in patients
and RCC in 2% of patients [13]. Further studies havewithout AD. On multivariable analysis (Table 5), age,
shed light on the prevalence, risk factors and naturalmale sex and dialysis duration were associated with AD,
history of both ARCD and RCC in ESRD patients (bothand again diabetes was inversely associated. Glomerulo-
before and after renal transplantation) [4, 5, 14, 15]. Mostnephritis was no longer significantly associated with the
of these studies have utilized ultrasound screening thatpresence of AD on multivariable analysis after adjusting
may have underestimated the true prevalence of RCCfor the confounding variables diabetes and the male sex.
due to limitations in resolution. Since we perform ipsilat-Patients with AD were more likely to have underlying
eral nephrectomy on most patients who undergo renalARCD (odds ratio 3.8 (1.8 to 7.9) (P  0.001).
transplantation, we have been able to construct a unique
Renal cell carcinoma database consisting of detailed histology on native renal
tissue from pre-transplant patients. Using this database,Twelve cases of renal cell carcinoma were identified
from the database. One case was reclassified as an onco- our current study reports the largest pathologic analysis,
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Denton et al: Renal cell carcinoma in ESRD 2205
Table 2. Univariable analysis of demographic and clinical characteristics of patients with ARCD (N  85) and without ARCD (N  175)
ARCD No ARCD
Odds ratio P value
Characteristic N (%) (CI) (Fisher’s)
Male 66 (77.7) 95(54.3) 2.9 (1.6–5.3) 0.001
White 69 (81.2) 138 (78.9) 1.2 (0.6–2.2) 0.869
Dialysis
All 74 (87.1) 135 (77.1) 2.0 (0.97–4.1) 0.068
HD 62 (72.9) 100 (57.1) 2.0 (1.2–3.6) 0.014
PD 12 (14.1) 35 (20.0) 0.7 (0.3–1.3) 0.303
Primary Disease
GN 39 (45.9) 56 (32.0) 1.8 (1.1–3.1) 0.039
DM 13 (15.3) 41 (23.4) 0.6 (0.3–1.2) 0.145
ARCD No ARCD
P value
Characteristic Mean (SD) (Wilcoxon RS)
Age years 45.8 (11.3) 41.2 (13.1) 0.0062
Dialysis duration years
Mean (SD) 3.1 (2.82) 1.28 (1.43) 0.0001
Median 2 1
Table 3. Multivariable analysis of demographic and clinicalto our knowledge, of the prevalence of ARCD, AD and
characteristics associated with ARCD
RCC in patients with ESRD awaiting renal transplanta-
Characteristic Odds ratio (CI) P valuetion. The strengths of this study are the large number
Age 1.0 (1.0–1.1)a 0.072of patients (which permitted multivariable analysis) and
Male 3.1 (1.5–6.3) 0.002the use of pathological data to determine precisely the
White 1.3 (0.6–2.8) 0.48
presence of ARCD, AD and RCC. Furthermore, as bi- HD 0.5 (0.2–1.3) 0.147
PD 0.3 (0.1–0.9) 0.04opsy of native kidneys is not always performed in pa-
Dialysis duration 1.9 (1.5–2.5)b 0.001tients with chronic renal failure, pathological analysis
GN 1.7 (0.8–3.3) 0.161
allowed better determination of primary renal disease DM 0.6 (0.3–1.5) 0.281
in some cases. Although this is a retrospective study, a Per year of age
b Per year on dialysissampling bias has been limited because all consecutive
cases were examined within the time period chosen, and
because pathologic analysis and data collection were per-
formed in a systematic manner. Furthermore, all cases of
with those of other groups [16–18]; however, in theseRCC were re-examined by an independent pathologist.
studies statistical analysis did not adjust for confoundingThe prevalence of ARCD reported here is similar to
variables. In our population, peritoneal dialysis was neg-that reported by Gulanikar et al, who screened a similar
atively confounded by a longer duration of dialysis. Dial-population of patients by ultrasound [4]. Consistent with
ysis duration was shorter in the HD group compared tomost previous reports [2], we found a strong association
the PD group probably because most patients who arebetween the prevalence of ARCD and dialysis duration,
destined for living related transplantation and thereforeeven after adjustment for other variables. When dialysis
a short course of dialysis are put on HD rather than PDmodality was examined by multivariable analysis, we
in our institution.found that patients on peritoneal dialysis were signifi-
cantly less likely to have ARCD. This finding contrasts We also found that ARCD was more common in males

Fig. 1. End-stage renal disease. (A) Macroscopic picture of bivalved kidney with acquired renal cystic disease (ARCD) and renal cell carcinoma
(RCC) (). (B) ARCD in a patient on chronic hemodialysis. The cysts are lined by flattened or cuboidal epithelium that form micropapillary
projections (H&E stain; original magnification; A, 200; B, 200). (C ) Papillary renal adenoma showing a microscopic nodular cortical lesion in
an end stage kidney. (D) Higher power of the papillary adenoma, densely packed tubulopapillary architecture lined by small cuboidal cells with
uniform nuclei that lack cytologic atypia (H&E, original magnification; C 100; D, 400). Renal cell carcinoma in end-stage renal disease cases:
(E ) Papillary renal carcinoma, tumor cells containing vesicular nuclei with prominent nucleoli arranged in papillary structures with fibrovascular
stalks. (F ) Conventional, clear cell renal carcinoma, sheets of tumor cells with abundant clear cytoplasm and central nuclei. Some tubular
differentiation and intervening vascular stroma are present. (G ) Chromophobe renal cell carcinoma, large tumor cells with abundant pale pink
cytoplasm with sharply defined borders, large pleomorphic nuclei and perinuclear clearing. (H ) Blue cytoplasmic staining for the presence of
colloidal iron, characteristic of chromophobe renal cell carcinoma (same tumor shown in G). (H&E stain, original magnification; E, 400; F, 400;
G, 400. Hale’s colloidal iron stain, original magnification; H, 400).
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Table 4. Univariable analysis of demographic and clinical characteristics of patients with adenoma (N  35)
and without adenoma (N  225)
Adenoma No adenoma
Odds ratio P value
Characteristic N (%) (CI) (Fisher’s)
Male 30 (85.7) 131 (58.2) 4.3 (1.6–11.5) 0.001
White 32 (91.4) 175 (77.8) 3.1 (0.9–10.3) 0.073
Dialysis
All 30 (85.7) 179 (79.6) 1.5 (0.6–4.2) 0.496
HD 25 (71.4) 137 (60.9) 1.6 (0.7–3.5) 0.265
PD 5 (14.2) 42 (18.7) 0.7 (0.3–2.0) 0.64
Primary disease
GN 19 (54.3) 76 (33.8) 2.3 (1.1–4.8) 0.024
DM 1 (2.9) 53 (23.6) 0.1 (0.01–0.7) 0.003
Adenoma No adenoma
P value
Characteristic Mean (SD) (Wilcoxon RS)
Age years 48.8 (10.3) 41.7 (12.8) 0.002
Dialysis duration years
Mean (SD) 2.99 (2.23) 1.71 (2.11) 0.001
Median 3 1
Table 5. Multivariable analysis of demographic and clinical analysis only. Here we found that diabetes mellitus was
characteristics associated with adenoma
negatively associated with AD on the adjusted analysis,
Characteristic Odds ratio (CI) P value an observation not previously reported. Others have
Age 1.04 (1.0–1.1)a 0.023 found that diabetics are less likely to have ARCD [22]
Male 6.8 (2.0–23.3) 0.002 and have suggested that this is because diabetics have a
White 3.3 (0.9–12.1) 0.067
shorter survival on dialysis. This would not explain ourHD 1.8 (0.4–7.5) 0.398
PD 1.3 (0.3–6.8) 0.729 findings since we adjusted for dialysis duration. Two pos-
Dialysis duration 1.2 (1.0–1.4)b 0.031 sible explanations are that (i) this was a chance finding
GN 1.6 (0.7–3.8) 0.281
or (ii) the diabetics in our study had a shorter total periodDM 0.1 (0.1–0.8) 0.034
of “exposure” to chronic renal failure  dialysis since,a Per year of age
b Per year on dialysis similar to other centers, diabetics in our units are often
started on dialysis at a higher GFR than non-diabetics.
Eleven cases of RCC were identified, giving a preva-
lence rate of 4.2%. This rate is over 100-fold higher than
[18]. Indeed, males tend to develop more extensive cystic that reported by Tosaka et al for a general unselected
changes, in addition to having a greater preponderance population on ultrasound screening [23]. Special consid-
for the disease [18, 19]. Previous reports have found an eration must be taken when extrapolating the prevalence
increased prevalence rate of ARCD in blacks [2]. No found in our study to that of the general ESRD popula-
significant racial predilection was found in our study al- tion. Firstly, we are sampling only one of two native
though numbers of non-whites were small. Finally, several kidneys so the true prevalence rate could actually double,
studies have reported an association between ARCD and that is, to 8.4%. However, 4 of 11 (36%) of our patients
primary glomerulonephritis [20, 21]. Although we found had bilateral renal cell carcinomas and Gulanikar et al
ARCD and glomerulonephritis to be associated on uni- (using radiological techniques) [4] found bilateral lesions
variable analysis, the association was not significant on in 2 of 8 (25%) patients. Thus, the true prevalence of
multivariable analysis. Thus, our series provides further renal cell carcinoma in our sample is between 4.2% and
confirmation of the clinical factors associated with ARCD 8.4%, approximately 30% less than the maximum preva-
identified by previous (radiology based) studies but, im- lence. Secondly, our sample population is not completely
portantly, does so by using “gold standard” pathology representative of the entire ESRD population due to
criteria and by using adjustment for confounding factors. the exclusion of non-transplant ESRD patients and some
Our study is the first to our knowledge to identify groups of pre-transplant patients that did not undergo
demographic and clinical characteristics associated with a native nephrectomy (for example, most patients with
the presence of AD in patients with ESRD. The overall reflux nephropathy). Our prevalence rate is greater than
prevalence of AD was 14%. Age, male sex and dialysis those reported by studies using ultrasound screening
duration strongly correlated with the presence of AD, (3.8% and 3.9% of ESRD patients pre- and post-trans-
plantation, respectively), probably because we were ableas did the presence of glomerulonephritis by univariable
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Table 6. Clinical and pathological characteristics of patients with RCC (N  11)
Primary Dialysis Multifocal Furhman
Age Sex Race disease Dialysis duration ARCD Adenoma CA grade Size Type
62 M W ESRD PD 3 Y Y Y 3 3.5 Papillarya
53 M H Nephrolithiasis NO 0 Y Y N 3 0.5 Chromophobe
54 M W Chronic GN HD 10 Y Y Y 3 1.2 Clear cell
51 M W DM HD 4.5 Y N N 2 1 Papillaryb
48 M W ESRD HD 4 Y Y Y 3 0.7 Papillaryb
53 M W MPGN HD 3 Y Y Y 1 0.2c & 0.5d Clear cell and papillarya
42 M H Chronic GN PD 1 Y N N 1 0.4 Clear cell
54 M W MGN HD 3 N Y N 2 0.8 Papillaryb
46 M W IgA NO 0 Y Y N 1 1.2 Clear cell
69 F B MGN HD 4 Y N N 1 1 Clear cell
51 M W IgA HD 4.5 Y Y N 2 0.5 Clear cell
Abbreviations are: DM, diabetes mellitus; FSGS, primary focal segmental glomerulosclerosis; MGN, membranous glomerulonephritis; ESRD, end-stage renal
disease; MPGN, membranoproliferative glomerulonephritis; IgA, IgA nephropathy.
a Eosinophilic type
b Basophilic type
c 0.2 cm clear cell carcinoma
d 0.5 cm papillary carcinoma
Table 7. Univariable analysis of demographic and clinical characteristics of patients with RCC (N  11) and without RCC (N  249)
RCC No RCC
Odds ratio P value
Characteristic N (%) (CI) (Fisher’s)
Male 10 (90.9) 151 (60.6) 6.5 (0.8–51.5) 0.056
White 9 (81.8) 198 (79.8) 1.1 (0.2–5.4) 1.0
Dialysis
All 9 (81.8) 203 (82.2) 0.8 (0.2–4.7) 1.0
HD 7 (63.6) 155 (63.5) 1.0 (0.3–4.7) 1.0
PD 2 (18.2) 45 (18.4) 0.9 (0.2–4.7) 1.0
Primary disease
GN 7 (63.6) 88 (35.3) 3.2 (0.9–11.2) 0.110
DM 1 (9.1) 53 (21.3) 0.37 (0.04–3.0) 0.470
RCC No RCC
P value
Characteristic Mean (SD) (Wilcoxon RS)
Age years 52.6 (6.4) 42.3 (11.7) 0.004
Dialysis duration years 3.0 (2.8) 1.8 (2.1) 0.134
Table 8. Multivariate analysis of demographic and clinical closely for RCC in a given histological specimen, we be-
characteristics associated with RCC
lieve the contribution of such bias is unlikely to have fully
Characteristic Odds ratio (CI) P value explained such a strong association. Furthermore, pa-
tients with ARCD, AD and RCC all shared commonAge 1.1 (1.0–1.2)a 0.013
Male 10.8 (0.8–149.0) 0.077 clinical characteristics. Although the number of patients
White 0.8 (0.2–4.4) 0.832 with RCC is too small to provide adequate statisticalHD 0.4 (0.1–2.8) 0.375
power for analysis, we found that RCC patients had thePD 0.6 (0.07–5.9) 0.688
Dialysis duration 1.3 (0.99–1.60)b 0.078 higher mean age of any group and all but one tumor
GN 3.0 (0.7–13.6) 0.143 occurred in males. There was also a trend towards longerDM 0.8 (0.1–9.1) 0.88
duration of dialysis in those with RCC compared to thosea Per year of age
without. Of note, only one patient with RCC had diabe-b Per year on dialysis
tes compared to seven with a primary renal diagnosis of
glomerulonephritis. These findings support the notion
to detect very small tumors. Indeed, three tumors were that ARCD, AD and RCC share common pathophysio-
less than or equal to 0.5 cm, which is below the minimum logic factors. Indeed, histopathologic studies of ARCD
size detectable by ultrasound scanning. have shown cellular changes suggesting that many of the
The majority of RCC occurred in the setting of ARCD RCC may have developed from papillary cystic hyper-
(91%) and AD (73%). Although the presence of ARCD plasia, in a manner analogous to the adenoma-carcinoma
sequence of the colon [24]. The pathogenic mechanismsmight have biased the reviewing pathologist to look more
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of cyst formation and RCC have not been elucidated. high [5]. Perhaps renal tumors developing in the setting
There is an enhanced expression of growth factors (plate- of ESRD represent a unique subtype of RCC with inher-
let-derived growth factor and epidermal growth factor) ent low metastatic potential. Kliem et al reported out-
and mutagens in end-stage kidneys although the mecha- come in 2372 renal transplant patients [33]; 12 cases of
nism promoting their expression is unknown [25, 26]. RCC were identified, of whom 4 died as a direct conse-
The uremic milieu seems to be an important factor; trans- quence of the tumor despite nephrectomy. Ondrus et al
plantation and restoration of normal renal function are reported 2 cases of metastatic RCC in 620 renal trans-
associated with regression of ARCD [27]. The strong plant patients [34]. In our series, no cases of metastatic
association with male sex suggests an important role for RCC developed in 349 patients transplanted during a
endogenous substances such as androgens. Failure of follow up period of 31.3  22.5 months. This may be an
immune surveillance due to immunosuppressive effects underestimate because first, the majority of our patient
of uremia may account for tumor development and the population already had one native nephrectomy, and
frequent multifocal nature of RCC in ESRD. second, a systematic search for metastatic RCC was not
Increasing evidence suggests that the genetic mecha- conducted in our study population.
nisms underlying development of RCC in the setting of In summary, our results suggest that renal tumors are
ESRD are different from those underlying sporadic RCC common in the pre-transplant ESRD population. Un-
in the general population. First, in ESRD there is an doubtedly, some of these cases may progress to more
overrepresentation of papillary RCC: whereas papillary invasive RCC. Current guidelines set by the American
RCC usually comprises only 10 to 15% of sporadic cases, Society of Transplant Physicians suggested that routine
in this study and others, papillary RCC represented over screening of transplant patients is not warranted. We
30% of tumors [28]. Second, sporadic papillary tumors suggest that a screening program aimed at those at high-
but not ESRD papillary tumor usually show allelic dupli- est risk of RCC merit further investigation and prospec-
cations of chromosomes 7 and 17 [29]. Typically RCC tive study. Our analysis suggests an effective method of
in the setting of ESRD is not associated with the p53 designing such a study because risk factors associated
gene mutation [14]. with the development of RCC in the ESRD population
Given the increased prevalence of RCC in patients are identified.
with ESRD, how aggressively should the dialysis and
Reprint requests to Mark D. Denton, M.D., Laboratory of Trans-transplant population be screened for RCC? Current
plantation and Immunogenetics, Brigham and Women’s Hospital, 75 Fran-practice is not to screen dialysis patients based on the
cis Street, Boston, Massachusetts 02115, USA.
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